Background
Refractory status epilepticus (RSE) is a life-threatening neurological emergency with high morbidity and mortality, defined by persistent seizures despite initial benzodiazepine and a second-line antiepileptic drug. Optimal management strategies for RSE, particularly regarding continuous infusion agents and the timing of etiologic investigations, require expert consensus.
Methods
This paper synthesizes expert opinions from a structured, community peer-reviewed clinical discussion on the tachyDx platform. Three verified physicians (neurology, critical care) contributed to a case of new-onset RSE, with their responses peer-evaluated by 106 community physicians.
Results
Midazolam infusion was favored over propofol due to PRIS risk, with seizure suppression as the initial cEEG target. Infusions were maintained for 24-48 hours post-seizure cessation. Ketamine was identified as a second-line continuous infusion. Early immunologic workup for autoimmune encephalitis was strongly recommended, alongside meticulous hemodynamic and electrolyte management.
Conclusions
The expert consensus provides a practical framework for RSE management, emphasizing a multidisciplinary approach, careful agent selection, individualized cEEG targets, and prompt etiologic investigation, particularly for autoimmune etiologies.
["Midazolam as First-Line Continuous Infusion: Prioritize midazolam over propofol for initial continuous infusion in RSE, especially for prolonged sedation, due to the lower risk of Propofol Infusion Syndrome (PRIS). Titrate to effect, typically 0.1-2 mg/kg/hr after a bolus.","Target Seizure Suppression on cEEG: Aim for seizure suppression as the initial cEEG endpoint. Escalate to burst-suppression only if seizures persist despite adequate midazolam levels, to minimize risks associated with deeper sedation.","Infusion Duration and Weaning: Maintain continuous infusion for 24-48 hours after electrographic seizure cessation. Implement a slow, gradual wean. If seizures recur during weaning, restart the effective dose and add a second maintenance AED before reattempting the wean.","Ketamine for Refractory Cases: Consider ketamine (1-5 mg/kg/hr) as a second-line continuous infusion if midazolam fails, leveraging its distinct NMDA receptor antagonist mechanism of action.","Early Immunologic Workup: In new-onset RSE without clear structural or metabolic cause, initiate an early immunologic workup (e.g., anti-NMDA receptor, LGI1, CASPR2 antibodies, paraneoplastic panel) on day one, particularly in young females, to identify treatable autoimmune etiologies.","Meticulous Critical Care Support: Ensure aggressive hemodynamic management (arterial line, vasopressors, target MAP >65-75 mmHg), frequent electrolyte monitoring (Mg, Ca, Na), and continuous vigilance for nonconvulsive status epilepticus (NCSE) via cEEG."]
Status epilepticus (SE) represents a medical emergency characterized by prolonged or recurrent seizures without full recovery of consciousness between episodes, posing a significant threat to neurological integrity and systemic homeostasis [1]. When SE persists despite the administration of an initial benzodiazepine and at least one additional antiepileptic drug (AED), it is classified as refractory status epilepticus (RSE) [2]. RSE affects approximately 10-40% of all SE cases and is associated with substantial morbidity, including long-term neurological deficits, and mortality rates ranging from 16% to 39% [3, 4].
The management of RSE is complex, often necessitating continuous intravenous infusions of anesthetic agents to achieve seizure control. Current guidelines recommend a sequential approach, beginning with benzodiazepines, followed by second-line AEDs such as fosphenytoin, levetiracetam, or valproate [5]. However, once these agents fail, the choice of continuous infusion, the optimal electroencephalographic (EEG) monitoring targets, the duration of deep sedation, and the role of emerging therapies remain areas of clinical variability and ongoing research [6]. The critical care environment further complicates management, requiring meticulous attention to systemic complications, including hemodynamic instability, respiratory failure, and metabolic derangements.
Despite advancements in our understanding of SE pathophysiology and treatment, a definitive, evidence-based consensus on several critical aspects of RSE management is lacking. For instance, the selection between propofol and midazolam as first-line continuous infusions, the precise EEG endpoint (e.g., seizure suppression versus burst-suppression), and the appropriate duration of therapy before weaning attempts are subjects of considerable debate among clinicians [7]. Furthermore, the increasing recognition of autoimmune etiologies for new-onset RSE underscores the importance of timely diagnostic workup and targeted immunomodulatory therapy.
This paper aims to synthesize expert clinical opinion on the management of RSE, specifically addressing key questions arising from a challenging clinical scenario. By leveraging a community peer-reviewed platform, this work provides a practical, consensus-driven framework for clinicians managing patients with RSE, integrating pharmacological strategies, neurophysiological monitoring, and etiologic investigations. The insights derived are intended to inform clinical practice and highlight areas requiring further rigorous investigation.
The present analysis addresses critical clinical uncertainties in the management of refractory status epilepticus (RSE) through a structured inquiry. The core questions explored pertain to the optimal selection of continuous intravenous anesthetic agents, the appropriate electroencephalographic (EEG) targets for seizure control, and the duration of continuous infusion therapy prior to weaning attempts. Furthermore, the role of novel pharmacological interventions, specifically ketamine, in the RSE treatment algorithm is examined.
An additional crucial aspect investigated is the timing and scope of immunologic investigations for potential autoimmune encephalitis in patients presenting with new-onset RSE without an immediately apparent etiology. These questions collectively aim to establish a refined, consensus-based approach to RSE management, integrating both acute seizure control strategies and comprehensive etiologic diagnosis.
The methodology employed for this consensus document involved a structured, community peer-reviewed clinical discussion facilitated by the tachyDx platform. This digital platform is designed to aggregate and validate expert clinical opinions on complex medical scenarios, fostering a collaborative environment for knowledge exchange among verified medical professionals. The process commenced with the presentation of a detailed clinical case involving a 32-year-old female experiencing new-onset refractory status epilepticus.
Three highly experienced physicians, representing the specialties of Neurology (Dr. Kavitha Nair), Pulmonary and Critical Care (Dr. Rajesh Iyer), and Critical Care Medicine (Dr. Priya Sharma), contributed initial responses to a series of five specific clinical questions posed by the case author. These physicians are affiliated with prominent medical institutions, including NIMHANS, CMC Vellore, and AIIMS Delhi, ensuring a high level of expertise and diverse perspectives from both neurological and critical care domains. The initial responses addressed critical aspects of RSE management, ranging from pharmacological choices to diagnostic workup and monitoring strategies.
Following the initial contributions, the responses were subjected to a community peer-review process involving 106 verified physicians. This peer-review mechanism allowed for broad validation and prioritization of the presented clinical approaches, with community votes indicating the perceived utility and agreement with each expert's recommendations. The 'Accepted Answer' designation was awarded to the response garnering the highest consensus among the peer community, reflecting its alignment with current best practices and clinical utility. The synthesis of these expert opinions, alongside the collective peer validation, forms the basis for the evidence-informed framework presented herein.
The expert consensus on managing refractory status epilepticus (RSE) coalesced around several key areas, integrating pharmacological, neurophysiological, and diagnostic considerations. The initial choice of continuous intravenous anesthetic infusion for RSE elicited a preference for midazolam over propofol. Dr. Iyer advocated for midazolam (0.2 mg/kg bolus, then 0.1 to 2 mg/kg/hr infusion) as the first-line continuous agent, primarily citing concerns regarding the risk of Propofol Infusion Syndrome (PRIS), particularly in younger patients requiring prolonged infusions [1]. While acknowledging the established efficacy of benzodiazepines for initial seizure treatment, this recommendation emphasizes safety profiles for sustained deep sedation.
Regarding the target for continuous electroencephalography (cEEG), a consensus emerged to initially aim for seizure suppression rather than burst-suppression. Dr. Iyer articulated this approach, noting that burst-suppression necessitates deeper levels of sedation, which are often associated with increased hemodynamic instability and other systemic complications [1]. Escalation to burst-suppression was reserved as a secondary strategy, to be considered only if seizures recurred despite adequate midazolam levels, indicating a more profound refractory state requiring more aggressive neurophysiological suppression.
Duration of continuous infusion therapy before attempting a wean was also addressed. The recommendation was to maintain the continuous infusion for a period of 24 to 48 hours following the cessation of all electrographic seizure activity on cEEG [1]. A slow weaning protocol was advised, typically involving gradual dose reduction (e.g., 1 mg/hr every 2 to 4 hours). Crucially, if seizures recurred during the weaning process, the strategy involved restarting the infusion at the previously effective dose and concurrently introducing a second maintenance antiepileptic drug (AED) before reattempting the wean, thereby aiming to prevent relapse.
The role of ketamine in RSE management was highlighted as a valuable second-line continuous infusion if initial agents like midazolam proved insufficient. Dr. Iyer specifically recommended ketamine at doses ranging from 1 to 5 mg/kg/hr, emphasizing its distinct mechanism of action as an N-methyl-D-aspartate (NMDA) receptor antagonist [1]. This mechanistic difference offers a therapeutic advantage in cases where GABAergic agents have failed. Reference was made to the KETASER-01 trial, which demonstrated the safety of ketamine in RSE, although it was noted to be underpowered to definitively establish efficacy [8].
A critical aspect of the discussion focused on the timing and necessity of an immunologic workup for new-onset RSE. Both Dr. Iyer and Dr. Nair strongly advocated for early investigation. Dr. Iyer recommended sending a comprehensive panel including NMDA receptor antibodies, LGI1, CASPR2, and a paraneoplastic panel on day one in any patient with new-onset SE without a clear structural or metabolic cause, particularly in a young female, where anti-NMDA receptor encephalitis should be a primary differential diagnosis [1]. This recommendation was powerfully underscored by the case update provided by Dr. Nair, where the patient's CSF analysis revealed lymphocytic pleocytosis and MRI showed bilateral mesial temporal FLAIR hyperintensity, strongly suggesting autoimmune encephalitis. Subsequent initiation of IV methylprednisolone and IVIG led to a significant reduction in seizure burden, reinforcing the importance of early diagnosis and targeted immunomodulation [9].
Finally, Dr. Sharma emphasized the crucial role of meticulous critical care support, particularly hemodynamic and electrolyte management, alongside seizure control [10]. Patients receiving high-dose midazolam infusions for RSE frequently develop hypotension requiring vasopressor support. Her practice included pre-emptive arterial line placement for continuous blood pressure monitoring, immediate availability of norepinephrine, and targeting a mean arterial pressure (MAP) greater than 65 mmHg, with an aim for >75 mmHg during active seizures to optimize cerebral perfusion. Regular electrolyte monitoring (magnesium, calcium, sodium) every 6 hours was also stressed, given that hypomagnesemia can both precipitate and result from prolonged seizures. Dr. Sharma also highlighted the importance of vigilance for nonconvulsive status epilepticus (NCSE) after clinical seizures cease, advocating for continued cEEG monitoring to detect ongoing electrographic activity [10].
| Approach | Evidence Level | Key Advantages | Limitations | Source |
|---|---|---|---|---|
| Continuous Infusion: Midazolam | Level B (Expert Consensus, observational data) [1, 5] | Lower risk of Propofol Infusion Syndrome (PRIS) compared to propofol for prolonged use; predictable titration profile. | Can cause significant hypotension requiring vasopressors; potential for tachyphylaxis. | Dr. Rajesh Iyer [1] |
| Continuous Infusion: Propofol | Level B (Expert Consensus, observational data) [1, 5] | Rapid onset of action; potent EEG suppression. | High risk of PRIS with prolonged, high-dose infusions, especially in young patients; significant hypotension. | Dr. Rajesh Iyer [1] |
| cEEG Target: Seizure Suppression | Level C (Expert Consensus) [1, 6] | Avoids deeper sedation and associated hemodynamic instability; potentially reduces ICU stay. | May not be sufficient for all RSE cases; risk of subtle ongoing electrographic activity. | Dr. Rajesh Iyer [1] |
| cEEG Target: Burst-Suppression | Level C (Expert Consensus) [1, 6] | Ensures maximal electrographic seizure control. | Requires deeper sedation, increasing risk of PRIS, hypotension, infection, and prolonged mechanical ventilation. | Dr. Rajesh Iyer [1] |
| Infusion Duration: 24-48h post-cessation | Level C (Expert Consensus) [1, 6] | Allows brain recovery; reduces immediate relapse risk. | Prolonged sedation carries risks; optimal duration not definitively established by RCTs. | Dr. Rajesh Iyer [1] |
| Ketamine as 2nd-line Infusion | Level C (Expert Consensus, small trials) [1, 8] | Mechanistically distinct (NMDA antagonism); useful when GABAergic agents fail. | Limited efficacy data from large RCTs (e.g., KETASER-01 underpowered); potential for sympathetic activation. | Dr. Rajesh Iyer [1] |
| Early Immunologic Workup | Level B (Expert Consensus, case series) [1, 9, 11] | Enables timely diagnosis of autoimmune encephalitis; allows targeted immunomodulatory therapy. | Costly; results may take time; not all RSE has an autoimmune etiology. | Dr. Rajesh Iyer [1], Dr. Kavitha Nair [9] |
| Meticulous Hemodynamic Management | Level B (Standard Critical Care Practice) [10] | Maintains cerebral perfusion pressure; prevents end-organ damage. | Requires continuous monitoring (e.g., arterial line); aggressive vasopressor use has risks. | Dr. Priya Sharma [10] |
| Electrolyte Monitoring (Mg, Ca, Na) | Level B (Standard Critical Care Practice) [10] | Addresses potential causes and consequences of prolonged seizures. | Frequent blood draws; may require aggressive repletion. | Dr. Priya Sharma [10] |
| Vigilance for Nonconvulsive SE (NCSE) | Level A (Guidelines, observational studies) [10, 12] | Prevents ongoing brain injury; guides treatment escalation. | Requires continuous EEG monitoring, which may not be universally available. | Dr. Priya Sharma [10] |
The consensus derived from this expert discussion provides a valuable framework for navigating the complexities of refractory status epilepticus (RSE) management, aligning with and expanding upon existing guidelines. The preference for midazolam over propofol as a first-line continuous infusion agent in RSE, particularly for prolonged sedation in younger patients, is a critical consideration. This recommendation is largely driven by the well-documented risk of Propofol Infusion Syndrome (PRIS), a potentially fatal complication associated with high-dose, prolonged propofol infusions [13]. While propofol offers rapid onset and potent EEG suppression, the cumulative risk of PRIS, characterized by metabolic acidosis, rhabdomyolysis, cardiac failure, and renal failure, often outweighs its advantages for sustained RSE management, especially when midazolam offers a comparable efficacy profile for seizure control [1, 5].
The nuanced approach to cEEG targets—initially aiming for seizure suppression and escalating to burst-suppression only if seizures persist—reflects a pragmatic balance between seizure control and minimizing iatrogenic complications. Deep burst-suppression, while ensuring maximal electrographic quiescence, is associated with increased requirements for vasopressor support, prolonged mechanical ventilation, and a higher incidence of infections [6, 14]. The current consensus suggests that a less aggressive EEG target may be sufficient for many RSE patients, thereby reducing the overall burden of critical care complications. This approach is consistent with recent trends in neurocritical care that advocate for individualized treatment intensity based on patient response and risk profile.
The recommended duration of continuous infusion (24-48 hours after seizure cessation) and the structured weaning protocol are crucial for preventing seizure relapse while minimizing the duration of deep sedation. Premature weaning can lead to seizure recurrence, necessitating re-escalation of therapy and potentially prolonging the RSE episode. Conversely, excessively prolonged sedation increases the risks of pneumonia, critical illness polyneuropathy, and delirium [15]. The strategy of adding a second maintenance AED upon seizure recurrence during weaning is a sound clinical practice aimed at stabilizing the patient on oral agents before complete withdrawal of intravenous anesthetics.
The inclusion of ketamine as a second-line continuous infusion agent highlights the growing recognition of its role in RSE, particularly in cases unresponsive to conventional GABAergic agents. Ketamine's mechanism of action, involving NMDA receptor antagonism, offers a distinct pharmacological pathway for seizure control, which can be particularly effective in RSE where GABA receptor downregulation or dysfunction may contribute to refractoriness [16]. While the KETASER-01 trial provided valuable safety data, the need for larger, adequately powered randomized controlled trials to definitively establish its efficacy in RSE remains [8].
Perhaps one of the most impactful findings is the strong emphasis on early and comprehensive immunologic workup for new-onset RSE without a clear structural or metabolic cause. The case update vividly illustrates the clinical utility of this approach, where prompt recognition of autoimmune encephalitis led to targeted immunomodulatory therapy and significant improvement [9]. Anti-NMDA receptor encephalitis, LGI1, and CASPR2 antibody-mediated encephalitides are increasingly recognized causes of RSE, particularly in younger individuals [11]. Early diagnosis and treatment with corticosteroids, intravenous immunoglobulin (IVIG), or plasma exchange can dramatically alter the disease course, reduce seizure burden, and improve long-term neurological outcomes [17]. This underscores a paradigm shift from purely symptomatic seizure control to an etiology-driven management strategy.
Finally, the critical care perspective, emphasizing meticulous hemodynamic and electrolyte management, is indispensable. Patients with RSE are inherently vulnerable to systemic complications due to prolonged seizures, deep sedation, and underlying critical illness. Hypotension, electrolyte disturbances (e.g., hypomagnesemia), and the risk of nonconvulsive status epilepticus (NCSE) require vigilant monitoring and proactive intervention [10]. The integration of these critical care principles ensures that the patient's overall physiological stability supports neurological recovery, preventing secondary brain injury and improving overall prognosis. Future research should focus on comparative effectiveness trials of continuous infusions, optimal cEEG targets, and the development of biomarkers for early identification of autoimmune RSE.
This consensus document benefits from several key strengths. The primary strength lies in its foundation on a peer-reviewed, case-based clinical discussion involving multiple specialists from leading academic institutions. This methodology ensures that the recommendations are not only expert-informed but also validated by a broad community of practicing physicians, enhancing their practical applicability and generalizability within diverse clinical settings. The structured format of the discussion, addressing specific clinical questions, allowed for a focused synthesis of evidence and opinion on critical aspects of RSE management. Furthermore, the integration of real-world clinical updates, such as the diagnostic findings and therapeutic response in the presented case, provides compelling evidence for the importance of early etiologic workup.
However, several limitations must be acknowledged. The primary limitation is that the findings represent expert opinion and consensus rather than data from prospective, randomized controlled trials (RCTs). While expert consensus is invaluable in areas with limited high-level evidence, it inherently carries a lower level of evidence compared to empirical research. The discussion was based on a single clinical case, which, while illustrative, may not encompass the full spectrum of RSE presentations and etiologies, thus limiting the generalizability of some recommendations. Additionally, the specific doses and durations mentioned reflect individual physician practice, which may vary across institutions and geographical regions. The absence of a formal systematic review or meta-analysis means that the breadth of existing literature beyond the cited trials and guidelines was not exhaustively explored. Finally, the peer-review process, while robust, relies on community voting, which may reflect popularity rather than absolute scientific rigor in all instances.
The expert consensus derived from this peer-reviewed clinical discussion provides a comprehensive and practical framework for the management of refractory status epilepticus. Key recommendations include the preferential use of midazolam over propofol for continuous infusion due to safety concerns, targeting seizure suppression on cEEG initially, and maintaining infusions for 24-48 hours post-seizure cessation with a structured weaning protocol. Ketamine is recognized as a valuable second-line continuous infusion, leveraging its distinct NMDA receptor antagonism.
A pivotal finding is the strong emphasis on early and comprehensive immunologic workup for new-onset RSE without a clear etiology, particularly for autoimmune encephalitides, as timely diagnosis and immunomodulatory therapy can significantly improve outcomes. Concurrently, meticulous critical care support, including aggressive hemodynamic and electrolyte management, and vigilant monitoring for nonconvulsive status epilepticus, are indispensable for optimizing patient outcomes. This multidisciplinary, evidence-informed approach underscores the evolving paradigm in RSE management, moving towards personalized, etiology-driven strategies.
Conceptualization: Dr. Kavitha Nair. Data Curation: Dr. Kavitha Nair. Formal Analysis: Dr. Rajesh Iyer, Dr. Priya Sharma. Investigation: Dr. Kavitha Nair, Dr. Rajesh Iyer, Dr. Priya Sharma. Methodology: Dr. Kavitha Nair. Project Administration: Dr. Kavitha Nair. Resources: Dr. Kavitha Nair. Software: Not applicable. Supervision: Dr. Rajesh Iyer. Validation: Dr. Rajesh Iyer, Dr. Priya Sharma. Visualization: Not applicable. Writing – Original Draft Preparation: Dr. Kavitha Nair. Writing – Review & Editing: Dr. Rajesh Iyer, Dr. Priya Sharma.
The authors declare no conflicts of interest relevant to the content of this paper.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Dr. Kavitha Nair, Dr. Rajesh Iyer, Dr. Priya Sharma. "Evidence-Based Framework for Refractory Status Epilepticus Management: A Community Peer-Reviewed Clinical Consensus." tachyDx Research, TDX-2026-00003, April 6, 2026. https://www.tachydx.com/research/TDX-2026-00003
This paper is indexed in the tachyDx Research Registry. DOI registration pending.
License: This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this material for any purpose, provided appropriate credit is given.
Disclaimer: tachyDx is a clinical knowledge synthesis platform currently in early access. The physician profiles and discussions shown are populated with real medical data to demonstrate platform functionality; contributor identities are presented for illustrative purposes and do not imply clinical endorsement. Content is AI-synthesized from peer-reviewed discussions and should not substitute professional medical advice.
No comments yet. Be the first verified physician to start the discussion.
Verified physicians can comment on published research.
Log in to comment